









## Hypertension 2017

Putting the Guidelines into Practice













### **Disclosures**

- Relationships with commercial interests:
  - Grants/Research Support:
  - Speakers Bureau/Honoraria:
  - Consulting Fees:
  - Data Safety and Monitoring:













## Disclosure of Commercial Support

- This program has received financial support from Servier in the form of an educational grant
- This program has not received any in-kind support
- Potential for conflict(s) of interest:
  - has received an honoraria funding from Servier, who has product(s) in this therapeutic area













## Mitigating Potential Bias

 The information presented is based on recent information that is explicitly "evidence-based" and is solely based on Hypertension Canada Guidelines













#### Evidence-Based Annual Guidelines

- Canada has the world's highest reported national blood pressure control rates
- Hypertension Canada is known as the most credible source for evidence-based hypertension guidelines, with annual updates, a well-validated review process and effective dissemination and implementation techniques across Canada













## Learning Objectives

At the conclusion of this activity, participants will be able to:

- Apply appropriate methods for making a diagnosis of hypertension
- Implement evidence-based threshold and target BPs
- Integrate new guidelines for hypertension management including:
  - Use of longer-acting over shorter-acting diuretics
  - Use of single pill combinations as a first-line treatment













## Hypertension 2017

#### What's new?

- Longer acting (thiazide-like) diuretics are preferred vs. shorter acting (thiazides)
- Single pill combinations as a first line treatment (regardless of the extent of BP elevation)













## Hypertension 2017

### What's still important?

- The diagnosis of hypertension should be based on out-of-office measurements; in the office, use automated office BP monitoring (AOBP)
- The threshold and target blood pressures are lower in those at greater risk













# Case 1. Office vs. Out-of-Office BP Measurements in the DIAGNOSIS of Hypertension: Which One to Believe?

- 57-year-old account executive presents for BP follow-up visit
- Elevated BP identified 2 months ago during annual exam
- Interim BPs taken at local pharmacies have all been normal
- Normal hematology, biochemistry, renal function and electrolytes
- Normal EKG with no evidence of LVH
- Office BP using auscultatory wall-mounted mercury sphygmomanometer: 152/102 mmHg
- How would you explain this observation?













## Hypertension Diagnostic Algorithm

- Out of office assessment is the preferred means of hypertension Dx
- 2. Measurement using electronic (oscillometric) upper arm devices is preferred over auscultation

Elevated BP Reading (office, home or pharmacy) Dedicated Office Visit<sup>1</sup> YES Mean Office BP ≥ 180/110 NO No Diabetes Diabetes<sup>3</sup> 1. AOBP2 ≥ 135/85 AOBP or (preferred) non-AOBP2 No Hypertension NO− ≥130/80 Hypertension<sup>6</sup> 2. Non-AOBP2 ≥140/90 (if AOBP unavailable) YES Out-of-office Measurement<sup>4</sup> 1. ABPM (preferred) Daytime mean ≥135/85 24-hour mean ≥130/80 - YES Home BP Series<sup>5</sup> Mean ≥135/85 NO White Coat Hypertension<sup>6</sup>

**ABPM** = ambulatory blood pressure measurement **AOBP** = automated office blood pressure










## Hypertension CANADA

## Out-of-Office Assessment is the Preferred Means of Diagnosing Hypertension















## Out-of-Office BP Measurements

- Out-of-office measurement identifies white coat hypertension and masked hypertension
- ABPM has better predictive ability than OBPM and is the recommended out-of-office measurement method
- HBPM has better predictive ability than OBPM and is recommended if ABPM is not tolerated, not readily available or due to patient preference














## Out-of-Office BP Measurements are More Highly Correlated With BP-Related Risk














## White Coat and Masked Hypertension














## The Prognosis of White Coat and Masked Hypertension














### Automated Office BP Measurement Preferred

 Automated office blood pressure (AOBP) is the preferred method of performing in-office BP measurement













### Automated Office BP Measurement

- More closely approximates ABPM than routine office BPs (mitigates white coat effect)<sup>1-3</sup>
- Is more predictive of end organ damage (LVMI, proteinuria and cIMT), similar to ABPM<sup>4-6</sup>

ABPM = ambulatory blood pressure measurement
LVMI = left ventricular mass index
cIMT = carotid intima media thickness

Beckett L, et al. BMC Cardiovasc Disord 2005;5:18; 2. Myers MG, et al. J Hypertens 2009;27:280-6;
 Myers MG, et al. BMJ 2011;342;d286;4. Campbell NRC, et al. J Hum Hypertens 2007;21:588-90;
 Andreadis EA, et al. Am J Hypertens 2011;24:661-6; 6. Andreadis EA, et al. Am J Hypertens 2012;25:969-73.













### Reflection Case 1

- What device do you currently use in the office to measure BP?
- What do you tell patients about home BP assessment?













## Hypertension 2017

## What's still important?

- The diagnosis of hypertension should be based on out-of-office measurements; in the office, use automatic office BP monitoring (AOBP)
- The threshold and target blood pressures are lower in those at greater risk











## Case 2. BP Control: A Moving Target?

- Jim is 76 years old, recent MI 2 years ago
- Comes to the office for hypertension follow-up, no residual angina
- Hypertension known for the last 20 years with BP ~135/80 mmHg average at home
- Rx: amlodipine 5 mg qd, olmesartan 20 mg qd, hydrochlorothiazide
   25 mg qd, bisoprolol 5 mg qd for hypertension
- Normal cardiovascular exam today, office BP 135/80 mmHg
- Normal hematology, LDL-C at target, creatinine and electrolytes within normal limits
- EKG with anterior infarct, no LVH, normal LV function on echo
- What should be his BP target?











## Usual Office BP <u>Threshold Values</u> for Initiation of Pharmacological Treatment

Population	SBP	DBP
High Risk (SPRINT population) #	≥ 130	NA
Diabetes	≥ 130	≥ 80
Moderate *	≥ 140	≥ 90
Low risk (no TOD or CV risk factors)	≥ 160	≥ 100

**AOBP** = automated office blood pressure

**TOD** = target organ damage

**SBP** = systolic blood pressure

**DBP** = diastolic blood pressure

# Based on AOBP

\*AOBP threshold ≥ 135/85 mmHg













## Recommended Office BP Treatment <u>Targets</u>

Treatment consists of health behaviour ± pharmacological management

Population	SBP	DBP
High Risk #	<u>≤</u> 120	NA
Diabetes	< 130	< 80
All others*	< 140	< 90













#### New Guideline Post-SPRINT

- For high-risk patients, aged ≥ 50 years, with systolic BP levels ≥130 mm Hg, intensive management to target a systolic BP ≤120 mm Hg should be considered
- Intensive management should be guided by automated office BP measurements
- Patient selection for intensive management is recommended and caution should be taken in certain high-risk groups













## New Thresholds/Targets for the High-Risk Patient Post-SPRINT: Who does this apply to?

Clinical or sub-clinical cardiovascular disease

OR

Chronic kidney disease (non-diabetic nephropathy, proteinuria <1 g/d, \*estimated glomerular filtration rate 20-59 mL/min/1.73m<sup>2</sup>)

OR

<sup>†</sup>Estimated 10-year global cardiovascular risk ≥15%

OR

Age ≥ 75 years

- There was an increased risk of renal deterioration, potassium abnormalities and hypotension with intensified therapy
- Patients with one or more clinical indications should consent to intensive management











## New Thresholds/Targets for the High-Risk Patient Post-SPRINT: Who does this NOT apply to?

#### **Limited or No Evidence:**

- Heart failure (EF <35%) or recent MI (within last 3 months)</li>
- Indication for, but not currently receiving, a beta-blocker
- Institutionalized elderly

#### **Inconclusive Evidence:**

- Diabetes mellitus
- Prior stroke
- eGFR < 20 ml/min/1.73m<sup>2</sup>

#### **Contraindications:**

- Patient unwilling or unable to adhere to multiple medications
- Standing SBP <110 mmHg</li>
- Inability to measure SBP accurately
- Known secondary cause(s) of hypertension











### Reflection Case 2

- Do you document BP targets on the patient's chart/EMR?
- How do you communicate BP targets to your patient?











## Hypertension 2017

#### What's new?

- Longer acting (thiazide-like) diuretics are preferred vs. shorter acting (thiazides)
- Single pill combinations should be used as a first line treatment (regardless of the extent of BP elevation)













## **Case 3.** Diuretics for Hypertension: A Fluid Situation?

- Matthew, a smoker, 53 years of age, is director of finances at your hospital
- A diagnosis of stage 1 HTN was made at his annual medical exam
   2 years ago
- He lost 15 pounds, walks to work everyday, but is unable to stop smoking
- HbA1c and lipids are normal
- No signs or symptoms of target organ damage
- His initial Rx was hydrochlorothiazide 25 mg qd but with home BP readings averaging 154/90 mmHg in the AM before meds and 132/84 in the PM
- You consider other options: leave things as they are? add another drug?













## Longer-acting Diuretics Should be Preferred

(i.e., thiazide-like are preferred to thiazides)

Longer-acting (thiazide-like): chlorthalidone, indapamide

Shorter-acting (thiazides): hydrochlorothiazide











## Diuretic Type Meta-Analysis vs. Placebo

- <u>Both</u> types of diuretics reduced CV events, cerebrovascular events, and HF
- Only thiazide-like diuretics additionally reduced coronary events and all-cause mortality

Event	Thiazide-Type	Thiazide-Like
CV	0.67 (.5681)	0.67 (0.60-0.75)
Coronary	0.81 (0.63-1.05)	0.76 (0.61-0.96)
Cerebrovascular	0.52 (0.38-0.69)	0.68 (0.57-0.80)
Heart Failure	0.36 (0.16-0.84)	0.47 (0.36-0.61)
All-cause Mortality	0.86 (0.75-1.00)	0.84 (0.74-0.96)












# Chlorthalidone More Effective Than Hydrochlorothiazide in BP Reduction

Hypertension



Kruskal-Wallis test used with Dunn's test for multiple comparisons; comparison between baseline and Wilcoxon signed rank test results. Mean 24h SBP was significantly lower for the chlorthalidone group than for the HCTZ group at week 4 (125.52 vs. 139.71 mmHg, respectively, P=0.019) and week 12 (121.87 vs. 136.64 mmHg, respectively, P=0.013). Intent-to-treat population.













## Summary: Longer-Acting Diuretics Preferred

 Longer-acting (thiazide-like) diuretics appear more effective at reducing CV events and SBP & DBP than shorter-acting (thiazide) diuretics













### Reflection Case 3

- In patients who are currently taking a short-acting diuretic and have good blood pressure control, should you change their therapy?
- How are you determining what constitutes good blood pressure control?













## Hypertension 2017

#### What's new?

- Longer acting (thiazide-like) diuretics are preferred vs. shorter acting (thiazide)
- Single pill combinations should be used as a first line treatment (regardless of the extent of BP elevation)













## Case 4. Lightening the Load in the Management of the Patient with Multiple Risk Factors

- Wally is a 59-year-old who has a remote history of prediabetes, mild hypertension and dyslipidemia. You haven't seen him for 3 years — he says "I just got tired of taking all those pills."
- Motivated by his family (older sib just had an MI), Wally presents for reassessment of his CV risks, with these results: BP 146/92, HbA1c = 6.8%, LDL = 3.9.
- As you consider his antihypertensive therapy, Wally says wistfully "Bet you're gonna load me up with pills again..."
- What antihypertensive therapy would you consider for this patient?














## First Line Recommendations Circa 1999-2016

TARGET < 140 mmHg systolic AND < 90 mmHg diastolic



A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is ≥20 mmHg systolic or ≥10 mmHg diastolic above target

<sup>\*</sup>Not indicated as first line therapy for patients over 60 yrs.












New 2017

## First Line Treatment of Adults with Systolic/Diastolic Hypertension Without Other Compelling Indications

TARGET <135/85 mmHg (automated measurement method)

INITIAL TREATMENT



<sup>\*</sup> Longer-acting (thiazide-like) diuretics are preferred over shorter-acting (thiazide) diuretics

§Renin angiotensin system (RAS) inhibitors are contraindicated in pregnancy and caution is required in prescribing to women of child bearing potential

\*\*Recommended SPC choices are those in which an ACE-I is combined with a CCB, an ARB with a CCB, or an ACE-I or ARB with a diuretic

<sup>†</sup>BBs are not indicated as first line therapy for age 60 and above











## Advantages of Single Pill Combinations (SPCs)

- SPC therapy is associated with better adherence vs. free combinations<sup>1</sup>
- A regimen featuring initial prescription of SPC leads to better BP control<sup>2</sup>
- Initial combination therapy is associated with  $\downarrow$  risk of CV events than monotherapy<sup>3,4</sup>

<sup>1.</sup> Sherrill B, et al. J Clin Hypertens 2011;13:898-909;

<sup>2.</sup> Feldman RD, et al. Hypertension 2009;53:646-53;

<sup>3.</sup> Corrao G, et al. *Hypertension* 2011;58:566-72;

<sup>4.</sup> Gradman AH, et al. *Hypertension* 2013;61(2):309-18.













## SPC Combining an ACEI/ARB With CCB/Diuretic as First Line Rx

### 2 key studies establishing the utility of SPCs as first line:

HOPE-3. N Engl J Med 2016;374(21):2009-20

Pivotal study demonstrating the superiority of an SPC (ARB/diuretic) vs. Placebo

ACCOMPLISH. *N Engl J Med* 2008;359(23):2417-28

Demonstration of efficacy of ACEI/CCB SPC vs. active control











### Reflection Case 4

- Will you start patients with newly diagnosed mild hypertension on single pill combination therapy?
- What are the barriers to prescribing SPCs?













## Hypertension 2017

#### What's new?

- Longer-acting (thiazide-like) diuretics are preferred vs. shorter-acting (thiazides)
- Single pill combinations as a first line treatment (regardless of the extent of BP elevation)











## Hypertension 2017

## What's still important?

- The diagnosis of hypertension should be based on out-of-office measurements; in the office, use automated office BP measurement (AOBP)
- The threshold and target blood pressures are lower in those at greater risk







ABOUT US | MEDIA | CONTACT US | DONATIONS





## hypertension.ca

#### For patients:

 Free access to the latest information and resources



▼ World Hypertension Day

#### For professionals:

- Accredited 15.5 hour interdisciplinary training program
- Free monthly news updates, featured research and educational resources

*Ivpertension* 

Become a member for special privileges and savings